Compare Comfort Systems USA Inc (FIX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Merck & Co., Inc. — how do they compare? Comfort Systems USA Inc trades at $1,660 (market cap $61.14B), while Merck & Co., Inc. trades at $127.93 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 5× Comfort Systems USA Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| FIX | MRK | |
|---|---|---|
Market Cap | $61.14B | $305.29B |
Sector | Technology | Health |
52-Week High | $2.07K | $129.52 |
52-Week Low | $532.14 | $77.60 |
Enterprise Value | $60.42B | $348.71B |
Dividend Yield | 0.15% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,694.14, down 4.56% amid bearish technical signals, though fundamentals remain strong with Q1 2026 EPS beating estimates at $10.51 versus $6.81 expected. Revenue growth is robust, projected to rise from $9.10B in 2025 to $10.1B in 2026, while net profit margins improve to 12.07%. The company benefits from AI infrastructure demand and a record backlog, though valuation multiples appear elevated with a P/E of 50.14.
Outlook is mixed: analyst consensus is bullish with a $2,100 price target and 55.56% buy ratings, but technical indicators signal near-term pressure. Key risks include execution challenges from rapid growth and premium valuation. The stock offers growth exposure to data center and construction markets, but investors should weigh high multiples against earnings momentum.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
